Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback